Over the last ten years, the approach to treating psoriasis in Argentina has notably changed, primarily driven by financial challenges and a significant dependence on affordable generic drugs. Frequent changes in currency value and limited healthcare funding have led dermatologists and medical practitioners to favor economical treatment methods, such as topical corticosteroids, vitamin D derivatives, and traditional systemic drugs like methotrexate and cyclosporine. These treatments are prevalent in both public hospitals and private practices because they provide effective disease management at a much lower price compared to newer biologic therapies. Local generic drug companies play a pivotal role in the national market, guaranteeing the availability of standard treatments even during tough economic times. Consequently, the strategy for treating psoriasis in Argentina has historically focused on practical prescribing habits that prioritize cost-effectiveness and accessibility over the quick incorporation of expensive innovations. Nonetheless, treatment guidelines are slowly changing as understanding of advanced therapies grows and some patients can access biologics through private insurance or specialized hospital programs.

Dermatology clinics in major cities like Buenos Aires, Córdoba, and Rosario are increasingly utilizing contemporary treatment pathways that align with standards, using targeted therapies for moderate to severe cases when financial conditions allow. Local medical associations and educational training have also enhanced diagnosis and treatment methods, promoted earlier interventions and coordinated care. Even with these improvements, economic circumstances still influence treatment choices, as doctors often have to weigh clinical effectiveness against what patients can afford and the limitations of insurance coverage. The treatment landscape for psoriasis in Argentina shows a mix of modern clinical methods in urban locales while retaining a significant dependence on generics and traditional treatments to ensure widespread access in a constrained healthcare system.According to the research report, " Argentina Psoriasis Treatment Market Overview, 2031," published by Bonafide Research, the Argentina Psoriasis Treatment market is anticipated to add to more than USD 96.40 Billion by 2026-31. The psoriasis market in Argentina functions within a complicated healthcare system marked by shifting public financing, economic instability, and diverse levels of access in both public and private medical facilities. Financial limitations and issues with reimbursements often curtail the extensive use of expensive biologic drugs, creating disparities in treatment access between urban centers and rural areas. Public health initiatives usually focus on essential medicines and affordable systemic treatments, while advanced biologics tend to be more accessible through private insurance or specialized treatment facilities.

Despite these challenges, growing awareness around dermatology through campaigns and educational programs is leading to earlier diagnoses and motivating patients to pursue treatment sooner, thereby enhancing long-term management of the disease. The nation's significant dependence on imported advanced treatments poses extra difficulties, as fluctuations in currency and complex regulations can impact pricing and the availability of products. Nevertheless, this reliance on imports also creates chances for the growth of locally produced generics and biosimilars, which can greatly lower treatment expenses and enhance access to advanced healthcare. Cost-effective systemic therapies continue to be a key element in managing psoriasis, especially for those with moderate severity, and are expected to remain prominent in Argentina’s treatment options. Furthermore, telemedicine platforms and digital health projects are starting to enhance access to dermatology care in areas that lack services, enabling patients to receive consultations and ongoing care without having to travel far. Pharmaceutical companies and healthcare providers are increasingly looking into collaborations to enhance patient education, adherence initiatives, and affordable treatment options.

Argentina’s psoriasis market is influenced by economic conditions but offers significant growth potential through low-cost therapies, local production initiatives, and increased healthcare awareness.Argentina psoriasis treatment market by treatment type is divided into biologics drugs, systemic drugs, topical drugs, phototherapy and others. In Argentina, plaque psoriasis represents the majority of diagnosed psoriasis cases, making it the central concern of dermatological care in public hospitals and private clinics. Initially, most patients receive topical corticosteroids or systemic treatments because they are more affordable, while biologic medications are mainly accessible in private health facilities or specialized urban locations like Buenos Aires and Córdoba. Increased awareness efforts and enhanced diagnostic training for healthcare workers are facilitating earlier identification of moderate-to-severe plaque psoriasis, which is encouraging a gradual shift towards the use of advanced treatment options as financial circumstances allow. Psoriatic arthritis is an expanding aspect of the psoriasis market in Argentina, fueled by a greater understanding of the condition’s systemic effects and the necessity for comprehensive care. Improved collaboration between dermatologists and rheumatologists has led to better diagnosis and treatment planning, especially for those patients who encounter joint difficulties.

While conventional systemic treatments are still prevalent due to financial limitations, targeted biologic options are becoming more available for individuals with private insurance or those who can access specialized clinics. The others category encompasses rarer types of psoriasis such as guttate, inverse, erythrodermic, and pustular forms. These types often necessitate specialized treatment in advanced hospitals due to their severity or complicated clinical features. While rural areas face challenges regarding access to modern treatments, telemedicine initiatives are starting to enhance the availability of specialist consultations. Argentina’s psoriasis market categorized by type showcases a blend of growing clinical sophistication in urban health systems alongside a persistent reliance on cost-effective solutions to maintain accessibility for a wide range of patients.Argentina psoriasis treatment market by treatment type is divided into biologics drugs, systemic drugs, topical drugs, phototherapy and others. The landscape of psoriasis treatment in Argentina is primarily shaped by systemic and topical therapies, largely influenced by economic factors and limitations in healthcare funding.

Systemic medications like methotrexate and cyclosporine are frequently utilized in public hospitals, as they offer effective control of the disease at a relatively low price. Topical treatments are the main choice for managing mild psoriasis and are routinely prescribed by general practitioners and dermatologists nationwide. These medications are available through local pharmacies and serve as the foundation for psoriasis treatment for many patients. Biologic medications are slowly gaining popularity in Argentina, particularly among those with moderate to severe conditions who can access private healthcare or specialized treatment initiatives. Nevertheless, high prices and challenges with reimbursement are ongoing barriers to their widespread use. Biosimilars represent a significant opportunity to enhance access to advanced therapies by providing more affordable alternatives.

Dermatology practices in major cities are increasingly beginning to integrate biologics into their treatment plans, following international clinical guidelines. Phototherapy continues to be an important treatment method, especially in dermatology departments of hospitals that have ultraviolet therapy equipment. While availability may be restricted in rural locations, phototherapy serves as an effective non-systemic option for those who are looking for alternatives to conventional medication. The others category encompasses new treatments like oral small-molecule inhibitors and combined treatment strategies that are designed to enhance treatment effectiveness. , Argentina’s treatment landscape illustrates a practical approach influenced by economic factors while slowly advancing toward more sophisticated therapeutic solutions.Argentina psoriasis treatment market by distribution channel is divided into hospital pharmacies, retail pharmacies and e-commerce. Hospital pharmacies are essential in the distribution of psoriasis treatments in Argentina, particularly for systemic medications, referrals for phototherapy, and advanced biologic therapies that require oversight from specialists. Public healthcare facilities often act as main treatment hubs for moderate to severe cases, offering integrated care and regulated distribution of medications.

Patients who need biologics generally depend on hospital pharmacies due to regulatory requirements and reimbursement protocols in public or private health insurance frameworks. Retail pharmacies serve as the most commonly used channel for psoriasis treatments across Argentina, notably for topical therapies and widely prescribed systemic medications. Community pharmacies are available in both urban and rural areas, making them integral to everyday disease management. Pharmacists frequently aid in medication counseling, tracking adherence, and providing patient education, which enhances treatment success and continuity of care. E-commerce and online pharmacy services are gradually gaining traction as digital health becomes more accepted. Even though regulatory measures remain stringent to protect patient safety and ensure adherence to prescriptions, online platforms are starting to offer easy access to medications along with home delivery options.

Telehealth consultations that gained popularity during the COVID-19 pandemic have quickened the shift toward digital prescriptions, especially in city areas. With the increasing availability of the internet and healthcare professionals leaning toward digital methods, e-commerce is likely to develop as an al distribution channel alongside traditional hospital and retail pharmacies, enhancing treatment availability for those in remote or underserved areas. Considered in this report* Historic Year: 2020* Base year: 2025* Estimated year: 2026* Forecast year: 2031Aspects covered in this report* Psoriasis Treatment Market with its value and forecast along with its segments* Various drivers and challenges* On-going trends and developments* Top profiled companies* Strategic recommendationBy TypePlaque PsoriasisPsoriatic ArthritisOthersBy Treatment TypeBiologics DrugsSystemic DrugsTopical DrugsPhototherapyOthersBy Distribution ChannelHospital PharmaciesRetail Pharmaciese-Commerce.